Ayla Debraekeleer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ayla Debraekeleer has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandar Murgaski
King’s College London 3 Centre for Inflammation Biology and Cancer Immunology, Cancer Research UK City of London Centre, School of Immunology and Microbial Sciences London, United Kingdom
36 shared publications - Daliya Kancheva
Lab of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium
36 shared publications - Damya Laoui
Laboratory of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium
36 shared publications - Helena Van Damme
Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium
36 shared publications - Jan Brughmans
Lab of Cellular and Molecular Immunology, Brussels Center for Immunology, Vrije Universiteit Brussel, Brussels, Belgium
36 shared publications - Louis Boon
JJP Biologics, Warsaw, Poland
36 shared publications
Latest Publications
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S9 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
Similarity between mouse/human tiTregs and the activation state of tiTreg subsets in E0771 model
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
Similarity between mouse/human tiTregs and the activation state of tiTreg subsets in E0771 model
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S11 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
IL1R2 is functionally redundant on tiTregs
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
IL1R2 is functionally redundant on tiTregs
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
Transcriptomic analysis of the different cell populations infiltrating human TNBC and CRC tumors
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
Transcriptomic analysis of the different cell populations infiltrating human TNBC and CRC tumors
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
TiTreg subsets in the MC38 model
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
TiTreg subsets in the MC38 model
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S10 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
Prediction of the active regulons in the different tiTreg clusters as determined via SCENIC
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
Prediction of the active regulons in the different tiTreg clusters as determined via SCENIC
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S14 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
Some TME immune components of E0771 and MC38 tumors when treated with anti-IL1R2 Nb-Fc monotherapy
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S14 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
Some TME immune components of E0771 and MC38 tumors when treated with anti-IL1R2 Nb-Fc monotherapy
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
Representative gating strategy for the different lymphoid and myeloid cell subsets infiltrating the TME
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
Representative gating strategy for the different lymphoid and myeloid cell subsets infiltrating the TME
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
TiTreg subsets in the E0771 model
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
TiTreg subsets in the E0771 model
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S13 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
Results of the monotherapy with different anti-IL1R2 Nb-Fc constructs in E0771 and MC38 tumor-bearing mice
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S13 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
Results of the monotherapy with different anti-IL1R2 Nb-Fc constructs in E0771 and MC38 tumor-bearing mice
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S15 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
Results of the therapy with the depleting anti-IL1R2 Nb-Fc construct 3 or the SDALIE-mutated, ADCC-enhanced construct 3, as monotherapy or in combination with anti–PD-1 mAb, in E0771 and MC38 tumor-bearing mice
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S15 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
Results of the therapy with the depleting anti-IL1R2 Nb-Fc construct 3 or the SDALIE-mutated, ADCC-enhanced construct 3, as monotherapy or in combination with anti–PD-1 mAb, in E0771 and MC38 tumor-bearing mice